Middle Country Family Medicine

Newsflash

Welcome To
Middle Country Family Medicine Website.

We Hope You Find
The Website Useful

Flu Season is Upon Us....
Don't forget to schedule an
appointment for a flu shot.

A federal panel recommended Wednesday that all children get an annual flu shot, dramatically expanding the pool of people who are urged to ward off the contagious respiratory illness -- and possibly paving the way for a universal flu shot recommendation.

The Advisory Committee on Immunization Practices, which makes recommendations to the Centers for Disease Control and Prevention, expanded the group of children who should get annual flu shots to include healthy children ages 5-18. Previously, the recommendation included only those 6 months to age 5.

Main Menu

Patient Information

Bookmark Us

Contact Information

Dr. Michael Randall
2539 Middle Country Road
Centereach, New York 11720
Tel: (631)580-1740
Fax: (631)580-9155

:: Contact Us ::
:: Directions ::

Plan route with GMaps

Plan your route to us

Visitors Counter

Visitors Counter 1.0.2

Home

Medical News

Medical Newsfeeds

Feed Name	# Articles
Swine Flu Updates	10
Clinical Trials / Drug Trials News	8
American Cancer Society	8
Psych Central	8
Cardiovascular / Cardiology News	8
Cancer / Oncology News	8
Bird Flu / Avian Flu News	8
Allergy News	8
ADHD News	8
Medscape Medical News	8
All DrugInfoZone News	8

Medical News (11)

Medical News Updates

Clinical Trials / Drug Trials News From Medical News Today
Latest Health News and Medical News posted throughout the day, every day.

Optimer Pharmaceuticals Announces Presentations Of Additional Fidaxomicin Phase 3 Data At Upcoming ICAAC Annual Meeting
Results from studies related to Optimer Pharmaceuticals, Inc.'s (Nasdaq: OPTR) lead developmental product candidate, fidaxomicin, will be presented at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) to be held at the Boston Convention and Exhibition Center in Boston on September 12-15, 2010...

Transdel Pharmaceuticals Presents Phase 3 Study Data On Ketotransdel® At World Pain Congress In Montreal, Canada
Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP), a specialty pharmaceutical company focused on developing topically administered products using its proprietary transdermal delivery platform, announced the final data set from its Phase 3 study of Ketotransdel® (TDLP-110) at the 13th World Congress on Pain in Montreal, Canada...

Soligenix Announces Publication Of Article Identifying Domains Within The Ricin Toxin A Subunit As Targets Of Protective Antibodies
Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced the publication of an article online in Vaccine. The article describes the systematic identification of neutralizing and non-neutralizing B-cell epitopes on ricin toxin's enzymatic A subunit (RTA)...

Inhibitex Successfully Completes Phase 1a Trial Of INX-189
Inhibitex, Inc. (Nasdaq: INHX), announced that it has successfully completed a Phase1a, first-in-man, single ascending dose trial of INX-189, its nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C (HCV) infections. In this trial, 42 healthy volunteers received either a single oral dose of INX-189, ranging from 3 mg to 100 mg, or placebo...

Halozyme Begins Phase 2 Clinical Trials With Insulin Analogs Lispro And Aspart With RHuPH20 In Type 1 And Type 2 Diabetes
Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced the initiation of two Phase 2 Ultrafast Insulin treatment studies that utilize its rHuPH20 hyaluronidase enzyme (PH20) in combination with the two leading commercially available mealtime analogs: insulin aspart, the active ingredient in NovoLog®, and insulin lispro, the active ingredient in Humalog®...

Eisai Announces The Start Of The First Clinical Study Of Ban2401, A Novel Monoclonal Antibody Targeting Neurotoxic Protofibrils
Eisai Co., Ltd. (Headquarters: Tokyo, Japan, President & CEO: Haruo Naito, "Eisai") announced today the start of the first patient enrolled clinical study with BAN2401, a novel monoclonal antibody that is being developed as a potential next-generation therapeutic treatment for Alzheimer's disease...

Trial To Test Experimental Drug For Advanced Pancreatic Cancer
Cancer Research UK's Drug Development Office has launched a clinical trial* to test an experimental drug in patients with advanced (Stage IV) pancreatic cancer - one of the most difficult cancers to treat. Around 60 patients with advanced pancreatic cancer will be recruited for the first Phase I/IIclinical trial of a drug called MK-0752** in this disease...

Roche Provides Update On FDA Application For T-DM1
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) issued a Refuse to File letter for accelerated approval for the company's trastuzumab-DM1 (T-DM1) Biologics License Application (BLA). As planned Roche will continue with its ongoing Phase III EMILIA registration study...